Clinical Trials Logo

Idiopathic Parkinson Disease clinical trials

View clinical trials related to Idiopathic Parkinson Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04459052 Active, not recruiting - Parkinson Disease Clinical Trials

FDOPA PET and Nutritional Support in Parkinson's Disease

FdopaPD2
Start date: April 30, 2020
Phase: Phase 2
Study type: Interventional

The overall goal of this study will be to further our understanding of how N Acetyl Cysteine (NAC) can help to support dopaminergic function in patients with Parkinson's disease (PD). We plan to use pre and post Positron emission tomography magnetic resonance imaging (PET-MRI) with [F-18] Fluorodopa (FDOPA) to measure dopamine function, and neurological measures to assess clinical symptoms, in patients with PD who are given oral capsules plus IV infusions of NAC in addition to standard of care for PD for 6 ±3 months in an open label cross over design. Serum measures of NAC concentrations, magnetic resonance spectroscopy (MRS) to measure inflammatory and oxidative stress markers, may be conducted.

NCT ID: NCT03683225 Active, not recruiting - Clinical trials for Idiopathic Parkinson Disease

A Study to Evaluate in Patients With Parkinsonian Type Disorders

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders

NCT ID: NCT02780895 Active, not recruiting - Clinical trials for Idiopathic Parkinson Disease

Parkinsonian Brain Repair Using Human Stem Cells

HSCfPD
Start date: May 2014
Phase: Phase 1
Study type: Interventional

Implantation of Celavie human stem cells (OK99) is intended to address the underlying pathology of the disease by replacing damaged/destroyed cells of the brain, and/or stimulating the patient's brain to repair itself.